Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Low-dose CDB 4124 (at doses of 1, 3, 6, 9 and 12mg) for the treatment of uterine leiomyoma and endometriosis

Next Previous
Trial Profile

Low-dose CDB 4124 (at doses of 1, 3, 6, 9 and 12mg) for the treatment of uterine leiomyoma and endometriosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telapristone (Primary)
  • Indications Endometriosis; Uterine leiomyoma
  • Focus Adverse reactions
  • Sponsors Repros Therapeutics

    • Most Recent Events

    • 17 Dec 2010 Planned number of patients changed to 60. According to a Repros Therapeutics media release, there will be 12 patients per dose cohort.
    • 17 Dec 2010 Status changed from not yet recruiting to recruiting. According to a Repros media release, patients in the 1mg dose cohort have completed 8 weeks of treatment, and dosing of the 3mg dose cohort will commence soon.
    • 27 Jul 2010 The Investigational Review Board approved the trial. Dosing of the first patient expected in the quarter 3 of 2010.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top